The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
Primary Purpose
Prostate Cancer
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
CARE-PC Web-Based Application
Sponsored by

About this trial
This is an interventional health services research trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria: Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of ADT Patients must be able to read and understand English. Exclusion Criteria: n/a
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Men With Prostate Cancer Planned for Receiving ADT
Arm Description
Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of systemic androgen deprivation therapy (ADT).
Outcomes
Primary Outcome Measures
CARE-PC Web-Based Application Completion Rate
Completion rate measured as the proportion of participants successfully completing the web-based application out of the total number of subjects approached.
Secondary Outcome Measures
Patient acceptance and perception of the web-based application
Acceptance/perception measured by brief embedded survey following participation in the web-based application
Percent accuracy of patient-derived CV- and prostate cancer-related data elements
Accuracy assessed through parallel medical chart review by cardiology and oncology clinicians
Prevalence of CV risk factors/disease at the time of CARE-PC web-based application participation
Prevalence assessed through parallel medical chart review by cardiology and oncology clinicians
Proportion of participants with current cardiologist involvement in CV care at the time of web-based application participation
Patient reported cardiologist involvement via CARE-PC application at time of application survey completion
Proportion of participants engaging in CV care within 6 months of CARE-PC web application participation
CV care engagement assessed through medical chart review by investigators within 6 months post-application survey completion
Proportion of participants having changes in CV risk-reducing medications within 6 months of CARE-PC application participation.
Proportion of participants having changes in CV risk-reducing medications assessed through parallel medical chart review by cardiology and oncology clinicians within 6 months post-application survey completion
Full Information
NCT ID
NCT06064149
First Posted
September 26, 2023
Last Updated
October 18, 2023
Sponsor
Vivek Narayan
Collaborators
National Comprehensive Cancer Network
1. Study Identification
Unique Protocol Identification Number
NCT06064149
Brief Title
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
Official Title
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC): Initial Pilot Feasibility Study to Assess Patient Awareness and Risk Mitigation
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 23, 2023 (Anticipated)
Primary Completion Date
June 30, 2025 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Vivek Narayan
Collaborators
National Comprehensive Cancer Network
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The overarching goal of this trial is to develop mechanisms to improve cardiovascular care among such prostate cancer patients receiving ADT by increasing patient awareness of individualized cardiovascular risk estimates and mitigation opportunities. Patients will be given access to a web-based quality improvement tool to educate patients of cardiovascular risks in prostate cancer and to inform them of their individualized, estimated cardiovascular risk and guideline-based risk mitigation recommendations.
The study will assess the feasibility of this web-based application as a cardiovascular education tool for patients with prostate cancer.
The study will also evaluate if completion of the web-based tool improves cardiovascular care access and risk mitigation for patients with prostate cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Men With Prostate Cancer Planned for Receiving ADT
Arm Type
Other
Arm Description
Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of systemic androgen deprivation therapy (ADT).
Intervention Type
Behavioral
Intervention Name(s)
CARE-PC Web-Based Application
Intervention Description
The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
Primary Outcome Measure Information:
Title
CARE-PC Web-Based Application Completion Rate
Description
Completion rate measured as the proportion of participants successfully completing the web-based application out of the total number of subjects approached.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Patient acceptance and perception of the web-based application
Description
Acceptance/perception measured by brief embedded survey following participation in the web-based application
Time Frame
18 months
Title
Percent accuracy of patient-derived CV- and prostate cancer-related data elements
Description
Accuracy assessed through parallel medical chart review by cardiology and oncology clinicians
Time Frame
18 months
Title
Prevalence of CV risk factors/disease at the time of CARE-PC web-based application participation
Description
Prevalence assessed through parallel medical chart review by cardiology and oncology clinicians
Time Frame
18 months
Title
Proportion of participants with current cardiologist involvement in CV care at the time of web-based application participation
Description
Patient reported cardiologist involvement via CARE-PC application at time of application survey completion
Time Frame
18 months
Title
Proportion of participants engaging in CV care within 6 months of CARE-PC web application participation
Description
CV care engagement assessed through medical chart review by investigators within 6 months post-application survey completion
Time Frame
18 months
Title
Proportion of participants having changes in CV risk-reducing medications within 6 months of CARE-PC application participation.
Description
Proportion of participants having changes in CV risk-reducing medications assessed through parallel medical chart review by cardiology and oncology clinicians within 6 months post-application survey completion
Time Frame
18 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of ADT
Patients must be able to read and understand English.
Exclusion Criteria: n/a
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew Doyle
Phone
610-357-6354
Email
matthew.doyle@pennmedicine.upenn.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vivek Narayan, MD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
We'll reach out to this number within 24 hrs